MT 2990
Alternative Names: MT-2990Latest Information Update: 16 Feb 2026
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Developer Mitsubishi Tanabe Pharma Corporation; Tanabe Pharma Corporation
- Class Analgesics; Anti-inflammatories; Antiallergics; Monoclonal antibodies
- Mechanism of Action Interleukin-33 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pain
- Phase I Vasculitis
- Discontinued Autoimmune disorders; Inflammation; Seasonal allergic rhinitis